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Background. Salvage liver transplantation (SLT) has been proposed for recurrent hepatocellular
carcinoma (HCC) after hepatectomy; however, it is unclear how the time interval to tumor recurrence
from previous hepatectomy affects prognosis.
Methods. We analyzed retrospectively the outcomes of 62 patients who underwent SLT in the Liver
Transplantation Center of the First Affiliated Hospital of Zhejiang University between 2001 and 2012.
SLT recipients were divided into 2 groups based on whether the time interval to recurrence was >1 year
(L group) or <1 year (S group).
Results. Baseline characteristics were similar between the 2 groups. The 1-, 3-, and 5-year overall
survival rates were 81%, 45%, and 45% in the L group, which were better than in the S group, with
47%, 21%, and 21%, respectively (P = .005). The corresponding tumor-free survival rates were
similar (P = .60) between 2 groups, with 71%, 51%, and 41% in the L group versus 55%, 55%,
and 55% in the S group. Macrovascular invasion (hazard ratio [HR], 3.30), greatest tumor diameter
(HR, 3.92), and time interval to tumor recurrence from previous hepatectomy (HR, 0.29) were inde-
pendent predictors for overall survival. Furthermore, the diameter of the largest tumor was the only
independent predictor of tumor-free survival (HR, 25.64).
Conclusion. The time interval to HCC recurrence from a previous hepatectomy is an important factor
associated with survival after SLT. This finding should be helpful in guiding patient selection criteria
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Open access under CC BY-NC-ND license.HEPATOCELLULAR CARCINOMA (HCC) is among the
most frequently reported malignancies in the
world, and its mortality rate ranks third in
cancer-related deaths.1,2 Operative interventions,
including hepatectomy and liver transplantation,
provide favorable survival rates for selected pa-
tients. Hepatectomy is the treatment of choice
for solitary tumors with well-preserved liver func-
tion, and the 5-year overall survival has been
reported to be as high as 70%.3-5 Despite this pos-
itive outlook, tumor recurrence owing to previous
underlying liver disease is a major factor impairing
patient survival. In this respect, Sapisochin et al6
observed that the cumulative risk of tumor recur-
rence rate was 69% at 5 years and 83% at 10 years
after hepatectomy, with a 10-year actuarial survival
of 33%.SURGERY 239
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240 Hu et alAlthough hepatectomy is a valuable interven-
tion, liver transplantation is the optimal treatment
of choice for many patients with HCC, because it
removes the tumor and can cure the underlying
liver disease.7-11 Unfortunately, there are an
increasing number of candidates on the waiting
list for liver transplantation and a donor organ
shortage, thereby limiting the utility of this treat-
ment option for patients with HCC.12,13 This prob-
lematic situation means that nearly one third of
patients with advanced HCC have been reported
to drop out of the liver transplantation waiting
list owing to tumor progression.14
Salvage liver transplantation (SLT), character-
ized by previous hepatectomy owing to HCC fol-
lowed by liver transplantation in case of tumor
recurrence, has been proposed to relieve the donor
liver shortage.15 Indeed, favorable long-term sur-
vival for patients who underwent SLT has been re-
ported.16 Our previous meta-analysis focusing on
SLT found that the 1-, 3-, and 5-year overall survival
rates, as well as the occurrence of major posttrans-
plant complications, were similar to patients under-
going primary liver transplantation.17
Despite the promise of SLT to relieve pressure
on liver transplantation waiting lists and provide
patients with a favorable prognosis, it is unclear
whether it is a feasible treatment option for all
patients who suffer from tumor recurrence after
hepatectomy. Specifically, previous studies have
shown that early recurrence after hepatectomy
was an important factor exerting the worst effect
on prognosis.18,19 In this context, there are con-
cerns that HCC patients who undergo hepatec-
tomy and develop an early tumor recurrence
might not be eligible candidates for SLT, although
this view has not been substantiated by evidence-
based medicine. In the current study, we studied
retrospectively whether the time interval to tumor
recurrence from previous hepatectomy was associ-
ated with the prognosis of patients undergoing
SLT.
PATIENTS AND METHODS
Patients. This single-center, retrospective study
was approved by the Liver Transplant Center of the
First Affiliated Hospital of Zhejiang University. All
data were obtained from the clinical records of
SLT recipients. Ethical approval was obtained from
the Committee of Ethics in Biomedical Research of
Zhejiang University, and written informed consent
was obtained from all participants. Sixty-two pa-
tients who underwent SLT between January 1,
2001, and December 31, 2012, at our center were
included in our analysis.Inclusion criteria were adult ($18 years old),
Chinese national, HCC patients who underwent
previous hepatectomy and received SLT owing to
tumor recurrence. Exclusion criteria were HCC
patients who underwent previous hepatectomy and
subsequent liver transplantation without tumor
recurrence, recipients with other types of liver
cancer (eg, cholangiocarcinoma), and were lost
to follow-up. All SLT recipients had hepatitis B
virus-associated HCC. The antiviral therapy for
hepatitis B recurrence was based on lamivudine
in combination with low-dose hepatitis B
immunoglobulin.
Study design. All patients underwent a regular
follow-up protocol according to diagnosis, man-
agement, and treatment of HCC carried out by
the Ministry of Health of the People’s Republic
of China after the initial hepatectomy, which
consisted of ultrasonography, computed tomo-
graphy, or magnetic resonance imaging scans,
and measurement of alpha fetoprotein (AFP)
levels (every 3 or 4 months for the first 3 years,
then every 4–6 month for the next 3–5 years,
then every 6–12 month after 5 years).
Patients were divided into 2 groups based on
the time interval to tumor recurrence after previ-
ous hepatectomy. If this time was >1 year
(including 1 year), they were assigned to the
long (L) group (n = 39), and if it was <1 year
they were assigned to the short (S) group
(n = 23; Table I). Patient follow-up occurred
routinely at our center, and our recurrence surveil-
lance strategy for recurrent HCC in SLT patients
was in accordance with the previous literature.20
The following prehepatectomy parameters were
compared between L and S group: Preoperative
AFP level, diameter of largest tumor, number of
tumors, tumor distribution, TNM staging, type of
hepatectomy, and macrovascular invasion. The
pretransplant clinical parameters were also
compared between the L and S group, including
age, sex, recipient blood type, donor–recipient
blood type incompatibility, pretransplant AFP
level, Model for End-stage Liver Disease (MELD)
score, TNM classification of malignant tumors,
Child-Pugh score, tumor number, diameter of
largest tumor, sum of tumor diameters, macro-
vascular invasion, cold ischemia time, warm
ischemia time, and intraoperative blood loss. The
immunosuppressive regimes used for maintenance
immunosuppression included tacrolimus, myco-
phenolate mofetil, and steroids, which were
divided into 3 groups based on different combina-
tions, namely triple regime (steroid plus tacroli-
mus plus mycophenolate mofetil), double regime
Table I. Classification of recipients who
underwent SLT
Classification
Recurrent time
interval <1 y
Recurrent time
interval >1 y Total
Within Hangzhou
criteria
13 22 35
Exceeding
Hangzhou
criteria
10 17 27
Total 23 39 62
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late mofetil), and single regime (either steroid,
tacrolimus, or mycophenolate mofetil). These
were also compared between the L and S groups.
Occurrence of major postoperative complications,
including biliary complications, vascular complica-
tions, postoperative infection, renal failure, and
acute rejection, were also assessed.
We also analyzed the 1-, 3-, and 5-year overall
survival and tumor-free survival rates from the date
of salvage transplantation, and compared these
rates between the L and S groups. We then
stratified all recipients using the Hangzhou
criteria: Patients without macrovascular invasion
who have 1 of the 2 following items---(a) total
tumor diameter #8 cm or (b) total tumor diam-
eter >8 cm; with grade I or II histopathology; and
preoperative AFP level # 400 ng/mL.20 Recipient
survival rates were further analyzed based on
whether (1) they met the Hangzhou criteria or
not, and (2) the time interval to recurrence was
>1 year. Based on these classifications, all patients
could be divided into 4 groups: (1) Recipients who
met the Hangzhou criteria in the L group (group
1; n = 22), (2) recipients who exceeded the Hang-
zhou criteria in the L group (group 2; n = 17), (3)
recipients who met the Hangzhou criteria in the S
group (group 3; n = 13), and (4) recipients who ex-
ceeded the Hangzhou criteria in the S group
(group 4; n = 10).
Statistical methods. Patient characteristics were
compared using a Student’s t test for continuous var-
iables and a Chi-square or Fisher’s exact test for
binomial variables where appropriate. Statistical as-
sociations between patient variables and survival
were evaluated using a univariate analysis. Those pa-
rameters that were found to be different (P # .05)
were further taken for the Cox regression analysis
using a forward likelihood ratio test. Differences
were considered statistically significant at a P # .05;
all tests were 2-sided. All the analyses were per-
formed using SPSS 16.0 (SPSS Inc, Chicago, IL).RESULTS
Patient characteristics. The clinical characteris-
tics of SLT recipients are shown in Table II. The
median follow-up time was 14 months (interquar-
tile range, 7–30) for all patients and was 9 months
(interquartile range, 5–18) for the S group and
18 months (interquartile range, 9–36) for the L
group. There were no differences observed be-
tween patients in the L and S groups in terms of
sex distribution, age, recipient blood type,
donor–recipient blood type incompatibility, preop-
erative AFP level, MELD score, Child-Pugh score,
TNM classification, tumor numbers, diameter of
largest tumor, sum of tumor diameters, macrovas-
cular invasion, cold ischemia time, warm ischemia
time, and intraoperative blood loss. The prehepa-
tectomy variables were also compared, and there
were no differences in the major parameters as-
sessed between the 2 groups (Supplementary
Table I; online version only).
Immunosuppressive regimes and posttransplant
complications. The immunosuppressive regimes of
the L and S group patients are summarized and
compared in Table III. Nine patients had a triple
regime, 18 had a double regime, and 12 had a sin-
gle regime in the L group; there were 5, 9, and 8
patients in each subset in the S group, respectively
(P = .895). Postoperative complications were
compared and detailed in Table III. No differences
existed between the L and S groups in terms of
postoperative biliary complications, vascular com-
plications, postoperative infection, renal failure,
and rate of acute rejection (all P > .05).
Survival analysis. In our analysis of all SLT
recipients, the 1-, 3-, and 5-year overall survival
rates were 68%, 37%, and 37%, respectively The
corresponding tumor-free survival rates at the
same time points were 66%, 51%, and 44%,
respectively. In the subgroup analysis, the 1-, 3-,
and 5-year overall survival rates were 81%, 45%,
and 45% in the L group, respectively. This was
significantly better than that for patients in the S
group, for which the overall survival rate at the
same respective time points was 47%, 21%, and
21% (P = .005; Fig 1). No differences were
observed in the 1-, 3-, and 5-year tumor-free sur-
vival rates in the L versus the S group, with 71%,
51%, and 41% in L group compared with 55%,
55%, and 55% in S group (P = .60; Fig 2).
Twenty-two SLT recipients (56%) met the Hang-
zhou criteria in the L group, and 13 (57%) SLT
recipients met these criteria in the S group. Based
on this finding, we reanalyzed our data to deter-
mine the survival rates in 4 different groups based
Table II. Clinical characteristics of patients in the L group and S group at the time of SLT
Characteristic L group S group P
Sex (male/female) 32/7 21/2 .318
Age (y) 49 ± 9 48 ± 9 .229
Transplant year (before 2008/after 2008) 11/28 12/11 .059
Blood type .950
A 12 7
B 11 8
O 12 6
AB 4 2
Blood type incompatible 4 5 .215
Preoperative AFP level, ng/mL 244.9 (15.5–834) 249.1 (20.55–7,331.5) .599
MELD score 9 (7–14) 10 (7–16) .553
TNM classification .750
I 11 7
II 10 4
III 13 7
IV 5 5
Child-Pugh score 7 (5–9) 7 (5–9) .976
Diameter of largest tumor (cm) 3.0 (2.0–5.0) 3.5 (2.0–4.0) .988
No. of tumors 2 (1–3) 2 (1–2) .977
Sum of tumor diameters (cm) 5.5 (3.1–9.6) 4.0 (2.5–8.0) .616
Macrovascular invasion 12 7 .978
Portal vein intrahepatic branch 2 0
Portal vein right or left branch 4 4
Main portal vein 5 3
Hepatic vein 3 0
Inferior vena cava 1 2
Cold ischemia time (h) 9.67 (7.17–11.87) 8.85 (7.20–11.18) .705
Warm ischemia time (min) 5.0 (3.5–5.0) 4.0 (3.5–5.0) .306
Intraoperative blood loss (mL) 2,670 (1,575–5,000) 2,000 (1,625–4,400) .596
Data are presented as number of patients, or median (interquartile range), or mean ± SD.
AFP, Alpha fetoprotein; MELD, Model for End-Stage Liver Disease.
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or not, and whether the time interval to recur-
rence was >1 or <1 year. SLT recipients in group 1
had the best prognosis with 1-, 3-, and 5-year
overall survival rates at 90%, 71%, and 71%,
respectively. This was compared with group 2
(62%, 37%, and 37%), group 3 (69%, 17%, and
17%) and group 4 (30%, nil, and nil), at the same
respective time points (all P < .05). Within groups,
group 2 had similar survival to group 3 (P = .650),
both of which were better than group 4 (both
P < .05; Fig 3). Our analysis of tumor-free survival
revealed no significant differences between these
different subgroups (Fig 4). Specifically, the
respective 1-, 3-, and 5-year tumor-free survival
rate in group 1 was 76%, 67%, and 50%; in group
2, it was 61%, 61%, and 61%; in group 3 it was
62%, 21%, and 21%; and in group 4 it was 53%,
nil, and nil (all P > .05).
Univariate analysis. Our univariate analysis
identified macrovascular invasion, year oftransplantation, TNM classification, diameter of
the largest tumor, warm ischemia time, and time
interval to recurrence after previous hepatectomy
to be significant predictors for overall survival.
Furthermore, the MELD score, total tumor diam-
eter, and diameter of the largest tumor were found
to be significant predictors for tumor-free survival
(Table IV and Supplementary Table II [online
version only]).
Multivariable analysis. According to the Cox
regression analysis, the independent predictors
for overall survival rates were as follows (Table
V): Macrovascular invasion (hazard ratio [HR],
3.30; 95% CI, 1.55–7.04; P = .002), the diameter
of the largest tumor (HR, 3.92, 95% CI, 1.53–
10.04; P = .004), and the time interval to recur-
rence after previous hepatectomy (HR, 0.29, 95%
CI, 0.14–0.61; P = .001). The only independent
predictor for tumor-free survival was the diameter
of the largest tumor (HR, 25.64, 95% CI, 5.20–
126.48; P < .001; Table V).
Table III. Comparison of immunosuppressive
regimes and posttransplant complications between
the L and S groups
Characteristic L group S group P value
Immunosuppressive regime* .895
Triple (steroid plus
tacrolimus plus
mycophenolate mofetil)
9 5
Double (2 of steroid, or
tacrolimus, or
mycophenolate mofetil)
18 9
Single 12 8
Posttransplant complications
Postoperative infectiony 3 1 .605
Biliary complicationsz 7 4 .956
Renal failurex 4 0 .292
Vascular complicationsjj 7 2 .531
Acute rejection 3 1 .605
*One patient did not have any steroids, tacrolimus, or mycophenolate
mofetil for immunosuppression.
yPostoperative infection includes pulmonary infection, catheter-related
sepsis, urinary tract infection, wound infection, opportunistic infection.
zBiliary complications include anastomotic biliary strictures, intrahepatic
biliary strictures, bile leakage.
xRenal failure includes chronic renal failure, acute renal failure and ure-
mia (excluding renal failure accompanied by hypertension and neonatal
uremia).
jjVascular complications include hepatic artery embolism, portal vein
embolism, portal vein stenosis/pylethrombosis, hepatic vein/inferior
vena cava stenosis/embolism.
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Liver transplantation is the preferred treatment
for many patients with HCC, because liver trans-
plantation both eliminates the tumor and cures
the underlying liver disease. Early experience with
HCC patients undergoing liver transplantation was
not satisfactory, and the tumor load has been
recognized increasingly as a dominant predictor
determining the success of liver transplantation.21
Thus, criteria for recipient selection have been
proposed for candidates with HCC to utilize maxi-
mally the donor organ pool, as well as achieving
satisfactory long-term survival. The Milan criteria
for patient selection were introduced in 1996 and
were associated with favorable overall survival rates
and low tumor recurrence.9 As demand for donor
livers increases, the Milan criteria have been
deemed too stringent by many groups, with many
candidates dropping off of the waiting list because
of death or tumor progression before they could
receive appropriate organ. In response to this situ-
ation, transplant centers around the world have at-
tempted to expand their criteria for recipient
selection to be more inclusive of patients with
HCC.22-24 In 2008, our center proposed the Hang-
zhou criteria, which achieves similar long-term sur-
vival to the Milan criteria.20Even for patients who meet the selection
criteria, donor liver shortages remain a major
limitation for treating HCC patients with liver
transplantation.13,25 In this context, primary hepa-
tectomy followed by SLT has been proposed as a
rational way to delay tumor progression for pa-
tients who are waiting for a suitable donor.
Although previous studies have validated that
SLT can achieve a similar prognosis compared
with primary liver transplantation, concern exists
in the field regarding patient eligibility for SLT.
In this regard, Tranchart et al26 evaluated the
pattern of tumor recurrence after initial hepatec-
tomy and found it to be a useful predictor when
considering the selection criteria for SLT. Chen
et al27 also reported that posthepatectomy time
to recurrence and the initial and recurrent charac-
teristics of the tumor were predictive factors for
posttransplant recurrent survival rates for HCC pa-
tients.27 Moreover, tumor recurrence within 1 year
after hepatectomy has a greater HR (41.3; 95% CI,
7.5–226.3) for 10-year overall survival than for tu-
mor recurrence 1 year after hepatectomy (HR,
4.9; 95% CI, 1.2–20.1).28 Taken together, these
studies indicate that initial tumor characteristics
at hepatectomy, the time interval to tumor recur-
rence after previous hepatectomy, as well as the
recurrent tumor profiles at transplantation might
be important prognostic factors in patients who
are candidates for SLT.
We analyzed the parameters that might possibly
affect prognosis for SLT recipients. The principle
finding is that the time interval to tumor recur-
rence after previous hepatectomy (using 1 year as a
cutoff) is an independent predictor of overall
survival in HCC patients undergoing SLT. Further-
more, when patients were stratified by the Hang-
zhou criteria, we observed that patients within the
Hangzhou criteria obtained superior survival rates.
These findings are consistent with our previous
report that SLT recipients within the Hangzhou
criteria achieve similar survival rates to those who
underwent primary liver transplantation, with 5-
year overall survival rates at 55% and 61%, respec-
tively. Importantly, our study shows that patients
whose time interval to tumor recurrence after
hepatectomy is >1 year and who, at the same
time, meet the Hangzhou criteria had the greatest
overall survival rates.
Interestingly, we observed that survival of those
recipients who underwent SLT has improved since
the proposal of Hangzhou criteria in 2008, as
depicted in the univariate analysis. The Hangzhou
criteria includes metrics of tumor biology (eg, AFP
and tumor histologic grade), highlighting the
Fig 1. Effect of time interval to tumor recurrence on overall survival. Overall survival rates after salvage liver transplan-
tation (SLT) in patients grouped according to whether the time interval to recurrence was >1 year (L) or <1 year (S).
Fig 2. Effect of time interval to tumor recurrence on tumor-free survival. Tumor-free survival rates after salvage liver
transplantation (SLT) in patients grouped according to whether the time interval to recurrence >1 year (L) or
<1 year (S).
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selection criteria, and the impact of these variables
on tumor recurrence.
The literature has already addressed tumor
recurrence patterns after hepatectomy. Thereported 5-year tumor-free survival rates for pa-
tients after hepatectomy range from 6 to
37%.27,29,30 It has also been reported that tumor
histopathology factors are important predictors
of tumor recurrence.31-33 Interestingly, different
Fig 3. Effect of time interval to tumor recurrence and Hangzhou criteria on overall survival. Overall survival rates after
salvage liver transplantation (SLT) in patients grouped according to whether they met the Hangzhou criteria in the L
group (group 1); exceeded the Hangzhou criteria in the L group (group 2); met the Hangzhou criteria in the S group
(group 3); or who exceeded the Hangzhou criteria in the S group (group 4).
Fig 4. Effect of time interval to tumor recurrence and Hangzhou criteria on tumor-free survival. Tumor-free survival
rates after salvage liver transplantation (SLT) in patients grouped according to whether they met the Hangzhou criteria
in the L group (group 1); exceeded the Hangzhou criteria in the L group (group 2); met the Hangzhou criteria in the S
group (group 3); or who exceeded the Hangzhou criteria in the S group (group 4).
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Table V. Multivariable analysis of variables related to post liver transplantation survival (Forward test)
Variables Group (reference group)
Overall survival Tumor-free survival
P Hazard ratio 95% CI P Hazard ratio 95% CI
Time interval to recurrence
after previous hepatectomy
$1 y (<1 y) .001 0.29 0.14–0.61
Diameter of largest tumor >5 cm (#5 cm) .004 3.92 1.53–10.04 <.001 25.64 5.20–126.48
Macrovascular invasion Yes (no) .002 3.30 1.55–7.04
Table IV. Univariate analysis of variables significantly related to post liver transplant survival (log-rank test)
Variables Cases
Overall survival (%)
Chi-square P value
Tumor-free survival
(%)
Chi-square P value1 y 3 y 5 y 1 y 3 y 5 y
TNM classification
I 18 70.0 61.3 61.3 8.245 .004
II 14 82.5 41.3 41.3
III 20 63.8 23.9 23.9
IV 10 50.0 10.0 10.0
Transplant year
Before 2008 23 52.2 21.7 21.7 5.209 .022
After 2008 39 77.0 50.2 50.2
Diameter of largest tumor
#5 52 74.0 41.4 41.4 8.448 .004 76.9 60.1 51.5 26.319 <.001
>5 10 30.0 0.00 — 0.00 — —
Warm ischemia time (min)
<5 30 56.7 26.7 26.7 4.563 .033
$5 32 79.0 47.6 47.6
Time interval to recurrence after previous hepatectomy (y)
$1 23 80.6 45.1 45.1 7.954 .005
<1 39 47.4 21.3 21.3
Macrovascular invasion
No 43 73.0 51.3 51.3 10.446 .001
Yes 19 56.4 7.3 7.3
Total tumor diameter (cm)
<8 41 77.4 61.0 45.7 6.231 .013
$8 21 41.7 13.9 13.9
MELD score
<15 46 57.5 41.5 31.1 4.056 .044
$15 16 86.7 77.0 77.0
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observed. For example, Portolani et al19 found 5
variables, including vascular infiltration, that were
associated with early recurrence, whereas only 1
variable was related to a late recurrence. This
finding was confirmed by Shah’s group, who found
vascular invasion and positive margins as predic-
tors for early tumor recurrence.18 Indeed, as Fuks
et al33 demonstrated, the strategy of SLT enables
the analysis of tumor profiles after the initially hep-
atectomy, thus allowing the prediction of HCC
recurrence patterns (whether or not the patients
meet the SLT criteria). In the current era of
extreme donor organ shortage, this approachcould help transplant surgeons to decide the
appropriateness of giving the patient the chance
of SLT or to choose tumorectomy, or other tech-
niques to eliminate recurrent tumors. Of note, in
the current study, we found no tumor characteris-
tics at initial hepatectomy that were different be-
tween L and S groups, and they were not
associated with posttransplant overall or tumor-
free survival.
Currently, a close relationship between preop-
erative AFP levels and patient long-term survival in
HCC patients has been emphasized.34,35 Merani
et al36 reported that HCC patients whose AFP level
could be decreased successfully to <400 ng/mL
Surgery
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survival rates to those patients with initially low
AFP levels. Indeed, these authors concluded that
the last AFP level at the time of liver transplanta-
tion was an independent predictor for posttrans-
plant survival.36 In another study, total tumor
volume and pretransplant AFP levels could predict
recipient survival efficiently.37 In this regard, pa-
tients in our study with greater times to tumor
recurrence after previous hepatectomy might
have a better tumor biology, so this group could
achieve a better prognosis after SLT.
Our study does have limitations. First, owing to
the retrospective nature of our study, there might
be confounding factors in our analysis associated
with unmeasured recipient characteristics. Second,
our study was limited by its small sample size; thus,
our findings should be validated in a prospective
multicenter study with a large sample size.
In conclusion, we describe the important role of
the time interval to tumor recurrence after previ-
ous hepatectomy in patients undergoing SLT. Our
results indicate that this variable is an independent
predictor for overall survival in recipients of SLT.
Specifically, patients with a time interval to tumor
recurrence of >1 year have a better prognosis than
patients who experience tumor recurrence within
1 year after hepatectomy. We believe this observa-
tion should be an important consideration when
guiding donor liver allocation for candidates with
a previous history of hepatectomy, to maximize
limited donor livers. Our results also indicate that
combining the time interval to tumor recurrence
with the Hangzhou criteria may be a powerful tool
for donor liver allocation. This report highlights
the importance of meticulous patient evaluation
for accurate prediction of prognosis in SLT
candidates.SUPPLEMENTARY DATA
Supplementary data related to this article can be
found online at http://dx.doi.org/10.1016/j.surg.2014.
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